Geron Corp. (NASDAQ:GERN)‘s stock had its “positive” rating reaffirmed by equities researchers at Wells Fargo & Co. in a research report issued on Thursday, AnalystRatings.NETreports. Geron Corporation (NASDAQ:GERN) stock performance was 5.62% in last session and finished the day at $1.78. Traded volume was 16,397,352 million shares in the last session and the average volume of the stock remained 5.30 million shares. The beta of the stock remained 1.67. Geron Corporation (NASDAQ:GERN) insider ownership is 0.10%.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) plans to start selling Northera in the second half of 2013. The company also intends to expand to pursue a label expansion for the Northera and to test it for the treatment of other norepinephrine-related conditions and diseases. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) rose 13.98 percent to $5.95 yesterday on volume of 11.85 million shares. The intra-day range of the stock was $5.13 to $6.11. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) has a market capitalization of $466.68 million.
TESARO, Inc. (Nasdaq:TSRO) announced an exclusive, worldwide license agreement and immuno-oncology antibody collaboration. Under the terms of the agreement, TESARO receives rights to monospecific antibody drug candidates targeting TIM-3, LAG-3 and PD-1 and dual reactive antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3. TESARO Inc (NASDAQ:TSRO)’s stock on Mar13, 2014 reported an increase of 27.49% to the closing price of $38.86. Its fifty two weeks range is $20.62 -$51.95. The total market capitalization recorded $1.40 billion. The overall volume in the last trading session was 3,455,221 million shares. In its share capital, TESARO Inc (NASDAQ:TSRO) has 32.45 million outstanding shares.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) witnessed a record number of call and put contracts during the busy trading session. There were 0.9 call contracts traded for each put contract yielding a 1.11 put/call ratio where 3,364 put and 3,024 call contracts exchanged hands. On Thursday, shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) advanced 9.63% to close the day at $17.53. Company return on investment (ROI) is -46.30% and its monthly performance is recorded as 46.94%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) quarterly revenue growth is 77.97%.